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Introduction :  
Anemia is defined as a hemoglobin (Hb)  level  less than 
13gram/deciliter (g/dl) in men and less than 12g/dl in women by the World 
Health Organization(WHO).
[1]
 Anemia affects a quarter of global population 
including 293 million children and 468 million non-pregnant women and the 
incidence is much higher in India
[2]
. The critical elements of erythropoiesis  
include erythropoietin (EPO), iron availability, proliferative capacity of the 
bone marrow and effective maturation of precursor cells in the marrow. These 
factors are involved in the causation of different types of anemia
.[3].
  
Correct assessment of the cause and type of anemia is essential for its 
treatment. The symptoms of anemia include fatigue, decreased work tolerance, 
shortness of breath, palpitations or other signs of cardiopulmonary adjustments 
to anemia
 [4,5]
. 
The evaluation of anemia includes a thorough history and physical 
examination followed by various investigations. The initial evaluation 
includes an assessment of whether anemia is associated with other 
hematological abnormalities. Further evaluation of anemia consists of 
assessment of reticulocyte response, peripheral smear study, a determination 
of iron indices, a bone marrow aspiration to study cell morphology and iron 
stores. 
Anemia is a common finding in patients diagnosed with cancer. Also, 
in such patients, the magnitude of anemia may be masked by a contraction of 
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plasma volume 
[6].
Anemia is widely prevalent in lymphoproliferative diseases 
even in patients without involvement of bone marrow and prior to initiation of 
chemotherapy 
[7, 8, 9].
   
The prognostic significance of anemia in Hodgkin lymphoma(HL) is 
well known and  is part of the International Prognostic Scoring System (IPSS) 
in  HL
[10]
 . The impact of anemia in prognosis of lymphoid malignancy is also 
evident in follicular lymphoma and is part of Follicular lymphoma 
International Prognostic Index (FLIPI)
[11].
 However, the prognostic 
significance of anemia in other subtypes of non-Hodgkin lymphoma (NHL) is 
not known and few studies have looked into this 
[7]
 
The present study titled “A prospective single-center study of the 
frequency and patterns of anemia in non-Hodgkin Lymphoma, with special 
reference to its impact on response to treatment and chemotherapy related 
toxicity” is a single centre study performed in a tertiary cancer care centre in 
south India. This study is conducted to assess the patterns of different types of 
anemia and its impact on attainment of response and chemotherapy induced 
toxicity in patients with NHL in our population. 
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The Aims and Objectives of the study are as follows: 
• To study the frequency of anemia in newly diagnosed patients with 
NHL 
• To analyze the patterns and causes of anemia in patients with NHL 
• To study the association of anemia with age , sex, stage and different 
subtypes of NHL 
• To study the association of anemia with attainment of Complete 
response(CR) and Partial response(PR) following treatment. 
• To study the association of anemia with chemotherapy related toxicity. 
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Review of Literature: 
Anemia: definition and prevalence 
Anemia is usually not a disease in itself; it is almost always a sign of an 
acquired or inherited abnormality. Red Blood Cells (RBC) have an average 
life span of 120 days and approximately 1% of RBCs are lost and replenished 
daily
[4]
. A reduction in the RBC mass resulting in anemia can occur due to 
increased loss, decreased production or both. Anemia can be functionally 
defined as an insufficient red cell mass to deliver oxygen adequately to tissues. 
Any of the three concentration measurements done on whole blood can be 
used to define anemia: the Hb concentration(g/dl), the hematocrit (Hct) or 
packed red cell volume(PCV) expressed in percent (%), or Red Blood 
Cell(RBC) concentration expressed in cells / microliter.
[4]
 However , the most 
commonly used parameter is Hb level. The WHO definition also incorporates 
Hb level as the parameter for assessment of anemia 
[1] 
Anemia is one of the most common hematological abnormalities 
encountered in clinical practice. According to western  literature , significant 
microcytosis occurs  in 3% of all patients who require hospital admission.
[12]
 
This is likely to be much higher in the Indian population , mostly due to 
nutritional causes
[2]
.  
Evaluation of anemia: 
Measurement of  the different parameters of anemia were done with 
manual techniques earlier. However, currently, they are measured by 
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electronic cell counters and Hb analyzers. From these values , Mean 
corpuscular volume(MCV), mean  corpuscular hemoglobin (MCH) and mean 
corpuscular Hemoglobin concentration(MCHC)can be measured as follows
[4].
 
MCV : ( Hct x 10 )/ red cell count x 10^6; normal value : 90+/-8  
femtolitre(fl) 
MCH: Hb x 10/ red cell count x 10^6; normal value: 30+/- 3pg 
MCHC: MCH/MCV; normal value: 33+/-2 % 
(2)
 
The electronic counters also measure an index called Red Cell 
distribution Width (RDW), which is a quantitative measure of the variation in 
red cell size 
[4]
. 
Initial evaluation of anemia consists of assessing whether it is 
associated with other hematological abnormalities. If yes, then bone marrow 
examination is done to look for leukaemia, myelodysplasia, myelofibrosis, 
aplastic anemia. If anemia is an isolated abnormality, then the reticulocyte 
response is assessed . Normal reticulocyte count by light microscopy is 
between 0.5-1.5%.Presently, automated methods are available. 
In the event of an adequate reticulocyte response, hemolytic and 
hemorrhagic causes are looked for. In the absence of an adequate reticulocyte 
response, red blood cell indices indicate the type of anemia 
[13]
 Measurement 
of corrected reticulocyte count(RC):
[14]
 
Reticulocyte =% of reticulocytes in RBC population 
Corrected RC=% reticulocytes x (patients’ Haematocrit)/45 
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Reticulocyte production index= corrected RC/ maturation time in 
peripheral time in days*  
( *Hct >/=40% :1 day, Hct 30-40%: 1.5 days, Hct 20-30%: 2 days, Hct 
<20%: 2.5 days)  
MCV can serve as a useful index in evaluating the cause of anemia: 
MCV more than 100 signifies macrocytic anemia and various causes 
such as folic acid and vitamin B12 deficiency have to be considered. MCV of 
80- 100 signifies normocytic anemia and anemia of chronic disease is the 
usual diagnosis. MCV less than 80 signifies microcytic anemia and causes 
such as iron deficiency, thalessemia, sideroblastic anemia , lead intoxication 
have to be looked into
.[4, 15 , 16,17]
. Further evaluation consists of peripheral 
smear study(PS), bone marrow aspirate(BMA) to look for cell morphology , 
marrow response and iron stores and evaluation of the iron indices 
(table1, 2, 3) 
Table 1: iron indices in different types of anemia 
[3]
 
Parameters Normal range 
Iron 
deficiency 
Inflammation 
Thalassaemia/ 
sideroblastic anemia 
Serum iron 50-150microg/dl <30 <50 Normal-high 
Serum ferritin 50-200microg/ L <15 30-200 50-300 
Total iron 
binding 
capacity(TIBC)  
300-360 microg/dl >360 <300 normal 
% saturation 30-50% <10 10-20 30-80 
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Table 2: normal marrow response to anemia 
[3]
 
Hematocrit 
Production 
index 
Corrected 
reticulocytes 
Marrow Myeloid:erythroid 
45 1 1 3:1 
35 2-3 2.5 2:1-1:1 
25 3-5 4 1:1-1:2 
15 3-5 4 1:1-1:2 
 
Table 3: iron store measurements in bone marrow 
[3,18]
 
Iron stores Marrow iron stain,0-4+ Serum ferritin,ug/L 
0 0 <15 
1-300mg Trace – 1+ 15-30 
300-800mg 2+ 30-60 
800-1000mg 3+ 60-150 
1-2gram 4+ >150 
Iron overload  500-1000 
 
Clinical features of anemia: 
1. cardiovascular and pulmonary features:  patients with chronic anemia may 
be asymptomatic till the Hb levels drop to 8g/dl or lower
[19] 
 Common 
manifestations include shortness of breath, fatigue, dizziness, palpitations, 
and in severe cases angina pectoris, intermittent claudication  and 
congestive heart failure
[5] 
2. Pallor : it is a sign of anemia and is best detected in the mucous membranes 
of mouth , pharynx, conjunctiva, lips and nail beds 
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3. skin and appendages: loss of  luster  and brittle hair, brittle nails, glossitis 
4. neuromuscular : headache, vertigo, lack of concentration, muscular 
weakness 
5. ophthalmologic signs: almost 20% patients have flame shaped 
hemorrhages, hard exudates, cotton wool spots and in some cases, 
papilledema is noted 
[20,21,22] 
6. gastrointestinal symptoms such as glossitis , dysphagia 
 
Common causes of anemia according to morphological type:
[3,4]
 
1. Macrocytic anemia: 
- Vitamin B 12 deficiency due to various causes 
- Folic acid deficiency due to various causes 
- Combined Vitamin B12 and folic acid deficiency 
- inherited disorders of   De oxy Ribonucleic Acid (DNA )synthesis 
- drug and toxin induced 
- alcoholism 
- liver disease 
- myelodysplastic syndrome 
- hypothyroidism 
2. Microcytic anemia 
a. disorders of iron metabolism  
- iron deficiency anemia 
- anemia of chronic disorders 
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b. disorders of globin synthesis 
- thalassemias 
- HbE disease 
c. sideroblastic anemias 
d. Lead intoxication 
3. Normocytic anemia 
a. anemia with appropriate marrow response: 
- post hemorrhagic anemia 
- hemolytic anemia 
b. decreased erythropoietin secretion 
- anemia of renal/liver disease 
- anemia of chronic disorders 
- protein calorie malnutrition 
c. anemia with impaired marrow response 
 - aplastic anemia 
- bone marrow infiltrative disorders 
- leukemia 
- myeloma 
- myelodysplastic anemias 
- early iron deficiency 
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Variation in Hb levels with age and physiology: 
It has been observed that anemia is a common occurrence in elderly 
persons and is probably related to decreased androgen levels or age- related 
decrease in stem cell proliferation 
[23].
 However, others have suggested that 
increased frequency of anemia in elderly is due to the underlying disease and 
have reported that RBC parameters of healthy elderly individuals are within 
normal range
[24].
Similarly, at the other extreme, Hb values in infants and 
children differ from adults
[4,25] 
  
 Blood volume adjustments also occur during pregnancy and puerperium 
[26]. 
Treatment: 
Treatment of anemia is directed at the cause of anemia 
Non-Hodgkins lymphoma (NHL): 
Epidemiology: 
Lymphomas (NHL and HL) are the fifth leading cause of cancer death     
and the second fastest growing cancer in terms of mortality. They constitute   
4-5% of all new cancer cases 
[10]
. The lowest incidence is reported from Asia 
[27].
There has been a striking rise in the incidence of NHL in the past four 
decades and the reason is mostly unexplained 
[28,29]
  
Etiology: 
Cause of NHL is mostly not known. Various genetic diseases, 
environmental factors and infectious agents may be involved in the causation 
of NHL. Inherited immunodeficiency states are associated with a 25% risk of 
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developing lymphoma
[30] 
In addition,  acquired immunodeficiency states such 
as HIV associated AIDS and organ transplantation  are associated with 
NHL
[31] 
Various infectious agents are associated with NHL such as: 
Epstein Barr Virus (EBV): Burkitts’ lymphoma, AIDS associated 
lymphoma, Post transplant lymphoprolferative disorders 
[32,33 ] 
Human Herpes Virus 8(HHV-8): primary effusion lymphoma, multi-
centric Castlemans’ disease[34]. 
Human T cell lymphotrophic virus (HTLV): Adult T cell leukemia / 
lymphoma 
[35,36] 
Helicobacter pylori infection: Mucosa Associated lymphoid Tissue 
(MALT) lymphomas 
[37]
  
Campylobacter jejuni: Immuno-proliferative small intestinal disorder
[38]
 
Borrelia burgdorferi: cutaneous B cell lymphoma
[39]
  
Chlamydia psittaci: ocular adnexal lymphoma (marzinal zone)
[40] 
Patients with autoimmune disorders such as rheumatoid arthritis, psoriasis and 
Sjogrens’ syndrome also have an increased risk of NHL [41] Classification of 
lymphomas: 
The 2008 WHO classification of NHL consists of 86 distinct subtypes 
of lymphoma 
[42]
. The WHO classification uses clinical, histological, 
phenotypic and genetic data, and provides a clinically useful system that can 
be applied throughout the world. 
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WHO classification of lymphoid neoplasms 2008: 
PRECURSOR B- AND T-CELL NEOPLASMS  
Precursor B-lymphoblastic leukemia/lymphoma  
Precursor T-lymphoblastic leukemia/lymphoma 
MATURE B-CELL NEOPLASMS  
Chronic lymphocytic leukemia/small lymphocytic lymphoma  
B-cell prolymphocytic leukemia  
Lymphoplasmacytic lymphoma/ Waldenstroms’ macroglobulinemia  
Splenic marginal zone B-cell lymphoma  
Hairy cell leukemia 
Splenic B cell lymphoma/leukemia, unclassifiable 
Splenic diffuse red pulp small B cell lymphoma 
Hairy cell leukemia variant  
Plasma cell neoplasms: 
Monoclonal gammopathy of undetermined significance 
Plasma cell myeloma  
Solitary Plasmacytoma of bone 
Extraosseous  plasmacytoma 
Monoclonal immunoglobulin deposition diseases  
Extranodal marginal zone B-cell lymphoma (MALT lymphoma)  
Nodal marginal zone B-cell lymphoma  
Follicular lymphoma 
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Primary cutaneous follicle center lymphoma 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma 
T cell/ histiocyte rich large B cell lymphoma 
Primary DLBCL of the central nervous system 
Primary cutaneous DLBCL, leg type 
EBV positive DLBCL of the elderly 
DLBCL associated with chronic inflammation 
Lymphomatoid granulomatosis  
Primary Mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK- positive large B cell lymphoma 
Plasmablastic lymphoma 
Large B cell lymphoma arising in HHV 8- associated multi-centric 
Castlemans’ disease  
Burkitts’ lymphoma/leukemia 
B cell lymphoma unclassifiable with features intermediate between 
DLBCL and Burkitts’ lymphoma 
B cell lymphoma, unclassifiable, with features intermediate between 
DLBCL and classic Hodgkins’ lymphoma 
MATURE T- AND NK-CELL NEOPLASMS 
T-cell prolymphocytic leukemia 
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T-cell large granular lymphocytic leukemia 
Chronic lymphoproliferative disorder of NK cells 
Aggressive NK-cell leukemia 
EBV positive T cell lymphoproliferative diseases of childhood 
Systemic EBV + T cell lymphoproliferative disease of childhood 
Hydroa vacciniforme – like lymphoma 
Adult T-cell leukemia/lymphoma 
Extranodal NK/T-cell lymphoma, nasal type 
Enteropathy-type T-cell lymphoma 
Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma 
Mycosis fungoides 
Sezary syndrome 
Primary cutaneous CD30 positive T-cell lymphoproliferative disorders: 
Primary cutaneous anaplastic large cell lymphoma 
Lymphomatoid papulosis 
Primary cutaneous peripheral T cell lymphomas, rare subtypes 
Primary cutaneous gamma-delta T cell lymphoma 
Primary cutaneous CD8 positive aggressive epidermotrophic cytotoxic 
 T cell lymphoma 
 Primary cutaneous CD 4 positive small/ medium  T cell lymphoma 
Peripheral T cell lymphoma, not otherwise specified  
15 
Angioimmunoblastic T-cell lymphoma 
Anaplastic large cell lymphoma, ALK positive 
Anaplastic large cell lymphoma, ALK negative 
IMMUNODEFICIENCY ASSOCIATED LYMPHOPROLIFERATIVE 
DISORDERS 
Lymphoproliferative diseases associated with primary immune 
 disorders 
Lymphomas associated with Human immunodeficiency virus infection 
Posttransplant lymphoproliferative disorders 
Plasmacytic hyperplasia and infectious mononucleosis like PTLD 
Polymorphic PTLD 
Monomorphic PTLD 
 Classic Hodgkins’ lymphoma type PTLD 
 Other iatrogenic immunodeficiency associated  
 lymphoproliferative  disorders 
Principles of Management: 
The appropriate management of patients with NHL include diagnosis, 
staging workup, prognostic scoring and baseline assessment of other organ 
systems .These include: 
- Accurate diagnosis from tissue biopsy with immunohistochemical and 
genetic studies 
- history and physical examination 
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- imaging and  studies : chest radiograph, computed tomography(CT) 
scans, positron emission tomography(PET) CT scans
[43]
 
- laboratory tests: complete blood count, biochemistry, tumor lysis 
parameters 
- bone marrow aspirate and biopsy 
- lumbar puncture in aggressive histologies and HIV associated 
lymphomas
[10]
 
Staging: 
The Ann Arbor staging system developed initially for staging patients 
with HL is used in staging NHL 
[44] 
Ann Arbor Staging System 
I. Involvement of a single lymph node region or a single extralymphatic organ 
or site (IE) 
II. Involvement of two or more lymph node regions on the same side of the 
diaphragm (II) or localized involvement of an extralymphatic organ or site 
(IIE) 
III. Involvement of lymph node regions on both sides of the diaphragm (III) or 
localized involvement of an extralymphatic organ or site (IIIE) or spleen 
(IIIS) or both (IIISE) 
IV. Diffuse or disseminated involvement of one or more extralymphatic organs 
with or without associated lymph node involvement. Bone marrow and liver 
involvement are always stage IV 
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Identification of the presence or absence of symptoms should be noted with 
each stage designation: A, asymptomatic; B, fever, sweats, weight loss greater 
than 10% of body weight. 
Prognostic index: 
The international prognostic index (IPI) is a valuable tool to stratify 
patients with NHL into different risk groups 
[45,46]
This includes five factors 
which  have an equal and independent effect on survival. These factors are: 
Age > 60 years 
Serum lactate dehydrogenase (LDH) >upper limit of normal 
Performance status (PS) > 2 
Advanced stage disease 
> 2 extra nodal sites 
The IPI is useful in risk stratifying almost all subtypes of lymphoma. 
However, it is less useful in certain types of lymphoma such as follicular 
lymphoma (FL) and mantle cell lymphoma (MCL) where separate predictive 
models are available such as Follicular Lymphoma International Prognostic 
Index (FLIPI) and Mantle cell lymphoma International Prognostic Index 
(MIPI) respectively. 
The FLIPI consists of the following factors: age >60years, stage 3 and 
4, Hb level<12g/dl, > 4 nodal areas involved and serum LDH above upper 
limit of normal 
[11] 
The MIPI consists of : age, PS , Serum LDH and Total 
White Blood Cell (WBC) count. 
[47]
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Treatment:  
The treatment recommendation for NHL is made after considering 
patient related factors (PS), type of lymphoma and disease stage. Most 
subtypes of NHL are treated with CHOP or CHOP-like chemotherapy 
regimens with or without rituximab(in B cell lymphomas) /Radiotherapy 
[48,49,50,51,52]
  
Anemia in cancer: 
Anemia is a common finding in cancer patients 
[6]
. Anemia occurs in 
over 30% of cancer patients at any point in time, and its incidence increases 
with treatment and as disease progresses. Causes of anemia in cancer patients 
are:  
1. Related to the patient :hemoglobinopathies,  gastrointestinal problems  
2. Secondary to the disease: bone marrow infiltration, bowel resection, 
 hypersplenism, poor nutrition 
3. Related to therapy : secondary to radiotherapy or chemotherapy 
A major symptom of organ disturbance is fatigue. In oncology, this 
symptom ranks first among patient complaints and correlates with  the 
hemoglobin level.Almost one third of patients become anemic after three 
cycles of chemotherapy .Several studies have shown that improving the 
hemoglobin level can improve quality of life in cancer patients and this is 
most marked when hemoglobin levels are increased to 11- 12 g/dL
[53] 
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Anemia in lymphoid malignancies: 
Anemia is reported in 40-80% patients with lymphoid malignancies 
[56] 
Several studies have looked into the prognostic significance of bone marrow 
involvement in NHL. However, very few studies have investigated the impact 
of anemia at diagnosis of NHL 
[57,58,59]
 
 
The impact of anemia as a prognostic factor in Hodgkin lymphoma is 
well known. Anemia can be an initial feature in approximately 40% of patients 
with HL. It is usually seen in advanced stages and in association with B 
symptoms .The anemia is usually a mild normochromic, normocytic in type   
with hemoglobin (Hb) levels between 10 and 12 g/dl. The inflammatory 
response around the Reed-Sternberg cell is part of HL .As a result of the 
reactive cells of the microenvironment, high levels of cytokines, such as IL-6, 
IL-10, and the chemokine thymus and activation-regulated cytokine (TARC) 
among others are secreted. These cytokines result in the development of 
systemic symptoms and laboratory abnormalities that are correlated with 
disease prognosis. Hence, anemia is incorporated in the prognostic scoring in 
HL. IL-6 is among the cytokines most strongly associated with anemia.
[60,61,62]
 
Anemia in NHL: Prevalence and prognostic significance 
Anemia is reported in approximately 50 % of NHL patients at 
presentation. 
[7,57,58,59,63]
 In one study, the prevalence of  anemia  in NHL was 
44.4 percent.  Women had a higher prevalence of anemia than men, but the 
severity was higher in men at the beginning and at the end of treatment.The  
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most common  anemia was anemia of chronic disease (53.8%), followed by 
anemia due to combined factors (anemia of chronic disease + iron deficiency 
anemia or anemia of chronic disease + hemolytic anemia). This was followed 
by anemia due to iron deficiency and hemolytic anemia. The authors 
concluded that prevalence of anemia as a consequence of the disease is high in 
lymphoproliferative disease and that chemotherapy had a minimal impact on 
anemia. In fact, there was a decline in the prevalence of anemia in NHL 
patients (44% Vs 21%) at the end of chemotherapy. However, the severity of 
anemia increased after chemotherapy in patients who had anemia at baseline 
[63]
 
A study of 1077 NHL patients found that anemia was the most common  
hematological finding at diagnosis  and was present in 32% of patients and it 
varied according to the subtype of lymphoma. The study also found that 
anemia was more common in patients with bone marrow involvement. 
Anemia was also significantly associated with certain patient characteristics. 
They found that a significantly larger percentage of anemic patients had the 
following characteristics: ≥60 years of age (39%), stage III or IV disease 
(37%), elevated LDH (47%), presence of B symptoms (61%), and ≥2 extra 
nodal sites (47%). They also found that the rate of complete response (CR) 
was lower in patients with anemia and in an univariate analysis, the overall 
survival (OS) and progression-free survival (PFS) were significantly shorter 
for anemic patients. 
[7]
 It was significantly associated with decreased PFS in 
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Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL) ,Diffuse 
large B cell lymphoma(DLBCL) and other high grade NHL and with shorter 
OS  in all subgroups except marginal zone lymphoma. 
[7] 
A study of anemia in 
Intermediate Grade NHL found anemia to be associated directly with other 
prognostic factors such as age>60, extra nodal sites>/=2, stage 3 or 4, elevated 
LDH and B symptoms. It was a retrospective study on the baseline prevalence 
and prognostic value of anemia in a group of patients with IGNHL. Thirty-five 
percent of patients in the study were anemic at baseline. They found that the 
prevalence of anemia varied with histological subtypes of NHL. In this study 
of intermediate-grade NHL, a larger percentage of anemic patients had the 
following histology subtypes: large cell immunoblastic(56%) and large 
cleaved or noncleaved cell/diffuse (38.9%)
[64].  
 
There is a conflict in published literature regarding the relationship 
between anemia and histology subtypes. This may result from the fact that 
these studies had a different patient distribution for different NHL grades. 
Moullet et al reported that the incidence of anemia was low in indolent 
lymphomas (17% in follicular and 19% in marginal zone lymphomas) with the 
exception of  small lymphocytic or lymphoplasmacytoid (37%)
[7] 
Conlan et al 
reported  that patients with high-grade lymphoma  have a higher prevalence of 
anemia than patients with intermediate-grade and low-grade lymphomas
.[65]
 
On the other hand, Bloomfield et al 
 
found no significant difference among 
histology types
[66]. 
Few studies have indicated that bone marrow involvement 
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was significantly associated with anemia 
[7,66]
Others have reported that even 
though bone marrow involvement is associated with anemia, it may not be at a 
significant level 
[65,67]
.
 
Many studies have determined that anemia prior to 
chemotherapy or radiotherapy can have a negative impact on survival and 
decreased response to therapy.  Morel et al
 
evaluated the factors associated 
with complete remission in patients with NHL and acute lymphoblastic 
leukemia and concluded that age >40, high LDH level, low Hb level (<10 
g/dl), and two or more extra nodal sites had a poor response to treatment 
[59].
 
Morrow et al also concluded that there is a significant association 
between baseline anemia and response to chemotherapy. Anemia was found to 
be associated with female sex , elevated LDH  , presence of B symptoms, 
advanced stage NHL (stage III or IV)  and large cell diffuse histology. 
[64]
     
These results indicate that the presence of baseline anemia was a 
significant risk factor for no response to CHOP chemotherapy even after 
controlling for a subset of the five commonly used factors in the International 
Prognostic Index.
 [7,65,66 ,67,68,69, 70] 
Another study evaluated anemia in 59 patients with diffuse large B cell 
lymphoma.  It was a retrospective study to determine the response to RCHOP 
therapy in DLBCL patients conducted between 2004 and 2009. PFS was 
measured from last RCHOP dose to the date of progression. Overall survival 
was measured from diagnosis to death or until December 2009. The median 
PFS for 54 patients who reached remission was 28 months (0.7-57+).and 
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median OS of all patients was 30 months (0.8-60+).  They found that 46% 
patients were anemic during treatment and had a lower rate of CR (59% vs. 
81%). Anemia was also associated with a higher mortality rate (37% vs. 16%), 
and median PFS [18 (0.7-52+) vs. 30 (2-57+) months] and OS [17 (0.8-59+) 
vs. 34 (5-60+) months] were shorter when compared to non-anemic 
patients
.[71]
   
A study from Delhi, India prospectively evaluated the prevalence of 
anemia in patients with lymphoid malignancy
[72].
 They evaluated newly 
diagnosed patients of lymphoid malignancy [non-Hodgkin lymphoma (NHL), 
Hodgkin lymphoma (HL), and chronic lymphocytic leukemia (CLL)] for 
anemia. The prevalence of anemia in patients with lymphoid malignancy was 
found to be 42.41% .It was multi factorial in 39.13 % patients. Anemia of 
chronic disease was the commonest cause of anemia and was present in 
71.74% patients. This was followed by nutritional anemia (iron, vitamin B12 
and folic acid deficiency) in 47.83% and Autoimmune hemolytic anemia in 
10.87% of patients. The authors concluded that although anemia of chronic 
disease is the commonest cause of anemia in patients with lymphoid 
malignancy, it is multi factorial in a large number of patients and hence it is 
important to rule out other causes of anemia. 
Correction of anemia needs correction of the cause. Nutritional anemia 
needs correction of the nutritional deficiency (iron, vitamin B12, Folic acid). 
Blood transfusion may be needed in severe anemia (Hb< 7g/dl).  Anemia of 
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chronic disease may respond to erythropoietin though there are concerns 
regarding the negative impact on survival reported with erythropoietin 
analogues. 
[6,8,71].
 
Anemia is a common hematological abnormality in NHL. The cause of 
anemia in NHL is usually multi factorial. The exact relevance of anemia in the 
setting of NHL is not known. However, it is likely that anemia may have a 
significant impact on the prognosis of NHL. Very few studies, and hardly any 
in India, have looked into the frequency and prognostic significance of anemia 
in NHL. Such studies are particularly important in the Indian setting where the 
prevalence of nutritional anemia is much higher and the impact of anemia, if 
any, on the overall prognosis may be much more relevant. Anemia, especially 
nutritional anemia is easily correctable, and hence, it is of utmost importance 
to know the impact of anemia on the prognosis or treatment related toxicity in 
NHL. The present study may help to throw some light on this aspect and have 
relevance on the management of patients with NHL, particularly in the Indian 
context. 
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Materials and Methods: 
This study is a prospective single - center study. 
Period of study: June 2011 to November 2012 
All patients with newly diagnosed NHL at our institute were screened 
for anemia. Anemia was defined as a hemoglobin level less than 13g/dl in men 
and 12 g/dl in women as per WHO definition of anemia. 
Inclusion criteria: 
• Age more than or equal to 15 years 
• Newly diagnosed patients with NHL (not previously treated) 
Exclusion criteria: 
• Age  less than 15 years  
• Patients with chronic kidney disease 
• Patients with known  hemoglobinopathies 
• Patients who have  received Blood transfusions or  have taken iron, 
folic acid or vitamin B12 supplements in the previous  two weeks  
• Patients with relapsed  NHL  
• Patients who have received treatment for NHL 
• Patients with lymphoblastic lymphoma were treated as per Acute 
lymphoblastic leukemia protocol and were excluded from the study  
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Patients included in the study were subjected to the following 
investigations to determine the cause of anemia: 
Peripheral blood studies: 
• Complete Blood Count(CBC) including total white blood cell count , 
hemoglobin , platelet count and differential count.   
• RBC indices: MCV, MCH , MCHC and hematocrit 
• Renal function test and Liver function test   
• Reticulocyte count, corrected reticulocyte count and reticulocyte index 
• Peripheral blood smear study(PS) 
• Direct Coombs’ test 
• Iron indices which includes  
- Serum iron (SI) 
- Serum ferritin 
- Serum Total iron binding capacity (TIBC) 
- Transferrin saturation 
• Patients found to have macrocytic anemia on  PS  with a reticulocyte 
count  suggestive of  hypoproliferative anemia  also underwent testing 
for serum vitamin B12 and folic acid levels 
• Bone marrow aspiration and biopsy studies: 
• morphology 
• Bone marrow iron study 
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Other studies: 
• C reactive protein (CRP) 
•  Routine Stool  examination  
•  occult blood  study  
•  gastrointestinal endoscopy as indicated in patients with  iron deficiency 
anemia   
All patients were staged as per Ann Arbor staging and IPI score was 
determined for each patient. Patients were subjected to complete re-staging 
investigations after four cycles of planned chemotherapy to assess response. 
Complete response (CR) , Partial response (PR) and stable disease(SD) 
were defined as per the  International Working Group (IWG) on Lymphoma 
Response Evaluation Criteria.
[73]
In  patients subjected to PET CT scans as part 
of  their staging evaluation, Cheson Criteria for Lymphoma was applied 
.[74]
 
Patients were assessed for toxicity after each cycle of chemotherapy and 
treatment related toxicity was graded according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (NCI- CTC AE) 
[75]
 
Definitions: 
Reticulocyte index (RI) was calculated in all cases. If RI was less than 
2.5, the patient was diagnosed to have a hypoproliferative anemia  
(normocytic / normochromic) or maturation disorder (micro/ macrocytic) 
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depending on the PS study. If RI was more than or equal to 2.5, the patient 
was evaluated for hemorrhage or hemolysis.
[3]
  
• Iron deficiency anemia(IDA) was diagnosed  by the following 
parameters: 
- transferrin saturation <20%  
- Serum ferritin (SF) <15 microgram/L and  
- Total iron binding capacity (TIBC)  >360ug/dl 
• Vitamin  B12 deficiency has been defined as a serum level < 
100ngm/ml in the presence of macrocytosis 
•  Folic acid deficiency has been defined as a serum level <4mcg/ml  in 
the presence of macrocytosis  
• Autoimmune hemolytic anemia (AIHA) was diagnosed if Coombs’ test 
was positive and hemolysis was evident on the peripheral smear 
• Anemia of chronic disease(ACD) was diagnosed by  
- transferrin saturation of  10-20%   ,  
- SF between 30-200ug/L and  
- TIBC of <300 microgram/dl  
• IDA+ACD was diagnosed if  
- transferrin saturation was <20  
- TIBC was <300microgram/dl and  
- SF was <30 microgram /L. 
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Red cell indices and marrow iron stores were evaluated as per standard 
reference ranges
[3] 
The following analyses were planned for the study:  
Frequency of anemia in patients with newly diagnosed NHL at our 
Institute will be analyzed with age and sex distribution. 
• Frequency of anemia in different subtypes of NHL  
• Distribution of different patterns of anemia in patients with NHL  
•  causes of anemia in patients with NHL  
• frequency  of anemia in different  stages of NHL   
• Any significant association of anemia  with bone marrow involvement, 
B symptoms or elevated LDH in NHL ( chi-square test) 
• Association  of anemia with attainment of complete response and 
partial response evaluated with chi-square test 
• Association of anemia with chemotherapy related toxicity (chi-square 
test/ Fishers’ exact test as applicable.) 
 (p value < 0.05  was considered   to be statistically  significant)   
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Results and observations:  
A total of two hundred (200) patients with newly diagnosed NHL were 
screened for anemia. Anemia was present in 144 / 200 (72%) patients. 
72%
28%
Anemic
Non-anemic
 
Figure 1 Frequency of Anemia 
Age-wise distribution of anemia in NHL patients (n=144): 
15-40 years: 28 /144(19.4%) 
41-60 years: 40/ 144(27.7%) 
> 60 years: 76/144(52.7%) 
Mean age of the study population was 54.2 years. Median age was 59 
years (range 18-75). Almost 53% patients with anemia were > 60 years of age. 
There was a statistically significant association of anemia with age > 60 
years (p value 0.02, chi square = 7.83) in patients with NHL. 
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Figure 2: distribution of anemic patients in different age groups (n= 200) 
Sex distribution: 
Among the 200 patients included in the study, 142 (71%) were males 
and 58 (29%) were females. 
SEX DISTRIBUTION
71%
29%
MALE
FEMALE
 
Among 144 patients diagnosed with anemia, 102 (71%) were males and 
42 were females (29%). Male: female ratio was 2.4:1 in anemic patients.  
There was no significant association of anemia with female sex 
(p=0.93, chi square=0.01, table 1 and bar diagram below). 
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 Male Female %of males % of females 
Anemic n=144 102/144 42/144 71% 29% 
non anemic n=56 40/56 16/56 71.4% 28.6% 
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Subtypes of NHL: 
Distribution of different subtypes of NHL among the 200 patients: 
Diffuse large B cell lymphoma (DLBCL): 129/200(64.5%) 
Follicular lymphoma (FL): 35/200(17.5%) 
Composite lymphoma (DLBCL+FL): 6/200 (3%) 
Mantle cell lymphoma (MCL): 10/200(5%) 
Others: 20/200(10%), which includes the following: 
Small lymphocytic lymphoma (SLL): 3/200 (1.5%), 
Angioimmunoblastic lymphoproliferative disease (AILD): 1 (0.5%) 
Anaplastic large cell lymphoma (ALCL): 6/200 (3%), 
Extranodal NK T cell lymphoma: 2/200 (1%),  
Splenic marzinal zone lymphoma(SMZ): 1/200 (0.5%), 
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 Lymphoplasmacytic lymphoma: 2/200 (1%), 
Cutaneous T cell Lymphoma(CTCL): 2/200 (1%), 
Burkitts’ lymphoma (BL): 3/200 (1.5%) 
Distribution of different subtypes of NHL in anemic patients (n=144): 
DLBCL: 90 (62.5%) 
FL: 29(20%) 
Composite lymphoma (DLBCL+FL): 6 (4%) 
MCL: 8(5%) 
Others: 11/144(7%), which includes the following: 
SLL: 2 (1.3%), 
AILD: 1 (0.6%), 
ALCL: 2 (1.3%) 
,Extra nodal NK T cell lymphoma: 1 (0.6%), 
SMZ: 1 (0.6%), 
Lymphoplasmacytic lymphoma: 2 (1.3%) 
CTCL: 1 (0.6%) 
BL: 1 (0.6%) 
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Figure 3 : distribution of different subtypes of NHL in the study population 
 
Figure 4:distribution of different subtypes of NHL in anemic patients 
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Anemia was commonly seen in high grade lymphomas. DLBCL was 
the type of lymphoma seen in 62.5% of anemic patients followed by follicular 
lymphoma, which was observed in 20% of patients. It was also observed that 
8/10 patients with MCL and 2/3 patients with SLL had anemia. However, the 
association of DLBCL and FL with anemia was not found to be statistically 
significant, (p=0.34, chi square= 0.90 and p=0.11, chi square=2.48 
respectively, tables 2a and 2b) 
Table 2a: DLBCL histology was not significantly associated with anemia.  
(p= 0.34) 
 
 Anemia present Anemia absent Total patients 
DLBCL 90 39 129 
Not DLBCL 54 17 71 
Total patients 144 56 200 
 
Table 2b:FL histology was not significantly associated with anemia 
(p=0.11). 
 
 Anemia present  Anemia absent Total no of patients 
FL  29 6 35 
Not FL 115 50 165 
Total patients 144 56 200 
 No particular subtype of NHL was found to be significantly 
associated with anemia in the study. 
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The stage-wise distribution of all patients with NHL was as follows: 
Stage No of patients ( n=200) 
I 10 (5%) 
II/ III 170 (85%) 
IV 20 (10%) 
Stage wise distribution in anemic patients: 
Stage No of patients(n=144) 
I 2(1.5%) 
II/III 124(86%) 
IV 18(12.5%) 
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Thus, majority of the patients (86%) were in stage II and stage III. 
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Bone marrow involvement was seen in 13 patients (among 20 patients 
with stage IV disease). All of these 13 patients had anemia. The association of 
bone marrow involvement with anemia was found to be statistically significant 
(p=0.02, Fisher exact test) 
Table 3: association of BM involvement and anemia (p=0.02) 
Bone marrow Anemia present Anemia absent Total patients 
Involved 13 0 13 
Not involved 131 56 187 
Total patients 144 56 200 
 
B symptoms were present in 25 %( 50/200) patients. Of these, 38 
patients (76%) were anemic and 12(24%) patients were non anemic. However, 
the association of anemia with B symptoms was not statistically significant . 
(p=0.47, chi square=0.53, table 4) 
 
B symptoms Anemia present Anemia absent Total patients 
Present 38 12 50 
Absent 106 44 150 
Total patients 144 56 200 
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Elevated LDH was found in 90% of patients with anemia (130/144). This 
association was not statistically significant.  
(p=0.83,chi square=0.04 table5 ) 
Elevated LDH Anemia present Anemia absent Total patients 
Present 130 50 180 
Absent 14 6 20 
Total patients 144 56 200 
 
The mean hemoglobin (Hb) was 10.7g/dl and median hemoglobin was 10.4 
g/dl (range 6.5-14.5). 
The distribution of different types of anemia was as follows: 
Normocytic normochromic anemia was seen in   108/144 patients (75%) 
Microcytic hypochromic anemia was seen in 30/144(21%) patients. 
Macrocytic anemia was seen in 6/144 patients (4%) 
75%
21%
4%
Normocytic normochronic
Microcytic hypochronic
Macrocytic
Distribution of different types of 
anemia
 
Thus, normocytic normochromic anemia was the most common 
morphologic type of anemia observed in the study 
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Etiology of anemia: 
Anemia of chronic disease (ACD): 70(48.6%) 
Iron deficiency anemia (IDA): 31(21.5%) 
Multi-factorial (IDA+ ACD): 35(24.3%) 
Vitamin B12 and folic acid deficiency: 6(4.2%) 
Autoimmune haemolytic anemia(AIHA) : 2(1.4%) 
ETIOLOGY OF ANEMIA
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Anemia of chronic disease was the most common cause of anemia. 
This was followed by multi factorial causes and nutritional causes.  CRP was 
elevated in all cases diagnosed to have ACD.  
Anemia and response to chemotherapy: 
Patients were reassessed after 4 cycles of chemotherapy for response 
with standard imaging, laboratory investigations and bone marrow study (if 
involved initially). Of all patients included in the study (n=200), 102 patients 
(51%) attained CR. Of these 102 patients, 52 patients (32%) were anemic and 
50 patients were not anemic (89%). Thus, CR in patients with anemia was 
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much less compared to those without anemia and this association was 
statistically significant on univariate analysis  
(p<0.001, chi square=45.6, table 6) 
After 4 cycles Anemia present Anemia absent Total patients 
CR present 52 50 102 
CR absent 92 6 98 
Total patients 144 56 200 
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When combined CR and PR responses were analyzed, it was observed 
that there was a statistically significant association between anemia and 
response to chemotherapy  
(p=0.04, chi square=4.38, table 7) 
 Anemia present Anemia absent Total patients 
CR/PR present 124 54 178 
CR/PR absent 20 2 22 
Total patients 144 56 200 
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Among 200 patients, twelve patients had stable disease and all had 
anemia at diagnosis. Ten patients had progressive disease of which eight 
patients had anemia. However, the association of progressive disease with 
anemia was not found to be statistically significant  
(p=0.82,chi square= 0.05,table 8) 
 Anemia present Anemia absent Total patients 
Progression 8 2 10 
No progression 136 54 190 
Total patients 144 56 200 
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In an univariate analysis, we a found significant association of older 
age with attainment of CR. Persons older than 60 years had lesser 
incidence of  CR  than those below 60 years (p=0.03,chi square=7.05). 
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Age> 60 years and presence of anemia were both significantly 
associated with lesser frequency of CR. Hence, multi factorial logistic 
regression analysis was done to determine the significance of each factor in 
association with attainment of CR. It was found that both age > 60 years and 
presence of anemia were independently associated with a higher risk of not 
attaining CR. Risk of not attaining CR was 17 fold higher in patients with 
anemia and 9 fold higher in patients aged more than 60 years compared to 
younger age  groups. Hence, anemia was significantly associated with a higher 
risk of lesser response to chemotherapy and the association was independent 
of age.  
Multi factorial logistic regression analysis: 
factor number 
Odds ratio of 
not attaining CR 
95% confidence 
interval 
Age group(years) 
15-40 
41-60 
>60 
 
28 
40 
76 
 
1.00 
1.38 
9.19 
p<0.001 
 
0.5-3.6 
3.5-23.7* 
Anemia absent 56 1.00  
Anemia present 144 17.19 6.3-46.4* 
 
* significant association with not attaining CR 
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Anemia and treatment related toxicity: 
Treatment related toxicity was seen in all patients. (n=200) 
The most common toxicity was neutropenia (198/200 patients) if all 
grades were considered. The two patients who did not have neutropenia were 
patients with CTCL who were treated with total skin electron beam 
therapy(TSEBT). The common toxicities observed were:  
Neutropenia:  Grade 3 and above: 80/200(40%) 
Thrombocytopenia: 50/200(25%), all were grade 1/2 
Febrile neutropenia : 70/ 200(35%) 
Chemotherapy induced nausea and vomiting (CINV): 65/200(32.5%) 
Neuropathy (vincristine related): 10 /200patients (5%) 
Cardio toxicity (anthracycline related, defined by a drop in ejection fraction by 
> 10% from baseline or clinical features of heart failure): 2/200(1%) 
 Nephrotoxicity: none 
Hepatotoxicity: none 
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Grade 3 or higher toxicity was seen in 80/200 patients (40%) and these 
were neutropenia / febrile neutropenia .Among cases with CINV (n=65), 50 
patients had grade 1 and 15 patients had grade 2 toxicity. All cases of 
neuropathy were grade 1.Vincristine dose was reduced/ omitted after 
documentation of neuropathy. Among two patients who had cardiotoxicity, 
one patient had grade 1 and the other had grade 2 toxicity.Two deaths 
occurred during the study period, the cause of death being progressive  
Burkitts’ lymphoma in one patient and neutropenic sepsis in the other. Hence, 
the treatment related mortality was 1/200 patients (0.5%). 
Of patients who had neutropenia (n=198), 143 patients were anemic 
and 55 patients were not anemic. There was no significant association of 
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anemia with neutropenia or grade 3 and higher toxicity including febrile 
neutropenia. 
All anemic patients with Hb <7 g/dl were transfused with packed red 
cells prior to initiation of chemotherapy as per our institute protocol. There 
was no worsening of anemia by >1g/dl in patients with baseline anemia after 
chemotherapy. Patients who did not have anemia at diagnosis did not develop 
anemia after chemotherapy.  
(p=0.48 chi square=0.49 ,table 9: neutropenia and anemia) 
 Anemia present Anemia absent Total patients 
Neutropenia  143 55 198 
No neutropenia 1 1 2 
Total patients 144 56 200 
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(p=.07, chi square=3.18, table 10: febrile neutropenia and anemia). 
 Anemia present Anemia absent Total patients 
Febrile neutropenia  45 25 70 
No febrile 
neutropenia 
99 31 130 
Total patients 144 56 200 
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Summary of results: 
Total number of patients analyzed: 200 
Patients with anemia: 144(72%); mean Hb: 10.7/dl; Median Hb:10.4 g/dl 
Most common pattern of anemia: normocytic normochromic anemia 
Most common cause of anemia: anemia of chronic disease 
Median age was 59years;Age >60 years significantly associated with anemia 
Male: female ratio in anemic patients is 2.4:1. No significant association with 
female sex. 
No significant association of anemia with specific subtype of NHL, B 
symptom, elevated LDH or chemotherapy related toxicity. 
Significant association of anemia was found with bone marrow involvement.  
Significant  association of anemia with attainment of response to treatment. 
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Figure A:Hypercellular bone marrow as a response to anemia 
( patient: serial no:103) 
 
 
Figure B: bone marrow in a patient with hypoproliferative anemia  
(patient :serial no 56) 
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Figure C: bone marrow iron study( 2+)(patient :serial no 50) 
 
 
Figure D:NHL with bone marrow infiltration ( patient:serial no 8) 
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Figure E: PS of a patient showing macrocytic anemia 
(patient:serial no 102) 
 
Figure F:PS showing microcytic anemia ( patient: serial no 31) 
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Figure G: PS of normocytic anemia(patient : Sl no 46) 
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Discussion:  
Anemia is reported to be a common hematological abnormality in 
cancer 
[6]
. The same was seen in our study. Anemia was observed in 72% of 
newly diagnosed patients with NHL. The frequency reported in our study is 
much higher compared to that of other studies reported in the literature.  This 
may be due to the fact that the cut off level of hemoglobin for the diagnosis of 
anemia was much higher in our study ( 13g/dl and 12g/dl in men and women 
respectively  as per WHO definition) whereas most of the studies reporting a 
lower frequency of anemia defined anemia as a hemoglobin level less than 11-
12g/dl
[7,72,64]
. Moullet has also mentioned that studies reporting lower 
frequency have used lower hemoglobin levels to define anemia 
[58,76,77]
  
 
Studies Frequency of Anemia 
Hb level used to define 
anemia(g/dl) 
Moullet et al(7) 32% </=12 
Morrow et al(64) 35% <12 
Ghosh et al(72) 42.41% <11 
Current study 72% 
62.5% 
 
<13males/< 12  female 
if cut off <11 is 
considered 
 
The higher frequency may also reflect a higher prevalence of anemia in 
the Indian population compared to the West
[2]
. It is noteworthy that Ghosh et 
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al from Delhi, India, reported a frequency of 42%, which was higher than the 
other studies even though the level of Hb used to define anemia was lower 
than most of the western studies 
[72].
In our study, the frequency of anemia was 
62.5% (125/200) even if we consider a cut-off Hb level of <11g/dl to define 
anemia, which is, still higher compared to other studies.  
Morrow et al reported a significant association of anemia with female 
sex.
[64] 
We, however, did not find a significant association of anemia with 
female sex. The most common type of anemia reported in our study was 
anemia of chronic disease (ACD) and it was observed in 49% of patients. This 
is in concordance with most of the studies. Ghosh et al and Dubravka et al also 
observed that ACD was the most common type of anemia in patients with 
NHL. They reported ACD in 71% and 53.8% of the patients respectively.
[72,63]
 
However, the frequency of AIHA was less in our study compared to others. 
The frequency of nutritional anemia was also lower in our study population.  
 
Studies ACD(%) Multifacorial% Nutritional(%) AIHA(%) 
Ghoshl[72] 71.74 39.13 47.83 10.87 
Our study 48.6 24.3 25.5 1.3 
 
Anemia of chronic disease is a commonly reported phenomenon in 
cancer 
[8]
 as well as in Hodgkin lymphoma and is probably related to cytokine 
release
[60,61,62]
. This is probably also the cause of anemia in most cases of 
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NHL. This is reflected by the elevated CRP values reported in all patients with 
ACD in our study. 
[78]
 
Anemia was observed in 53 % of patients aged more than 60 years. On 
univariate analysis, we found a significant association of anemia with age 
more than 60 years. A similar finding is reported in other studies 
[7,59,64]. 
 
Studies % of patients >60years 
p value for association 
with anemia 
Morrow et al[64] 61.4 0.0416 
Moullet et al[7] 39 <0.001 
Current study 53 0.02 
      
The association of age with prognosis in NHL is well known and is 
included in the IPI 
[45,46]
. It is, therefore, noteworthy that anemia is 
significantly associated with age> 60 in most studies. The cause of anemia in 
elderly is multi-factorial. It has been reported that anemia is common in 
elderly population by some studies 
[23]
 .On the contrary, other studies have 
refuted this.
[24]
. However, age seems to have a significant association with 
anemia as well as with attainment of CR after treatment.  
Our study did not find a significant association between anemia and the 
presence of B symptoms. There was also no significant association between 
anemia and elevated LDH. This is in contrast to certain studies that have 
reported significant association of anemia with B symptoms as well as with 
elevated LDH 
[7,64]
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Studies 
B symptoms in 
anemia (%) 
P value 
Elevated LDH 
in anemia (%) 
P value 
Moulletl[7] 19 <0.0001 47 <0.0001 
Morrow [64] 51.4 <0.0001 52 0.001 
Current study 26 0.47 90 0.83 
   
We found a much higher percentage of patients having elevated LDH. 
This may be due to a larger number of patients with high-grade lymphomas 
included in our study.  
Our study did not find a significant association of anemia with any 
particular histological subtype of NHL. 
There is a lack of consistency in literature regarding the relationship 
between anemia and histological subtypes of NHL. This may be because of 
the fact that various studies had a different distribution of patients with 
different grades of NHL. Moullet et al observed that the incidence of anemia 
was lower in indolent lymphomas (17% in follicular and 19% in marginal 
zone lymphomas) except in small lymphocytic or lymphoplasmacytoid (37%) 
lymphoma.
[7]
 Conlan et al observed that patients having high-grade lymphoma 
had a lower median hemoglobin value and a higher prevalence of anemia than 
patients with intermediate  or low-grade  lymphomas
[65]
. On the other hand, 
Bloomfield et al did not find a significant difference among histology types as 
regards to the incidence of anemia 
[66]
.  Morrow et al observed that the 
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prevalence of anemia varied with histology subtypes. 
[64]
 Moullet et al 
suggested that increased cytokine production may be responsible for the 
variation in anemia patterns based on histology subgroups. 
[7]
   This study 
observed that a larger percentage of anemic patients had the following 
histology subtypes: large cell immunoblastic and large cleaved or noncleaved  
cell . 
Our study found a significant association between bone marrow 
involvement and anemia (p=0.02). All patients (n= 13) with bone marrow 
involvement were found to have anemia. This is in concordance with some 
other studies.  There are conflicting reports in literature regarding bone 
marrow involvement and anemia in lymphoid malignancies. Both Moullet et 
al and Bloomfield et al observed
  
 that bone marrow involvement was 
significantly associated with anemia (p<0.0001) 
[7,66].
 But others have reported 
that although bone marrow involvement was associated with anemia, it was 
not statistically significant 
[65, 67] 
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[67] 
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We found a significant association of anemia with complete response 
and complete /partial response in patients with NHL. We observed a 
statistically significant association of anemia as well as age with complete 
response in univariate analyses. Age more than 60 years was significantly 
associated with both anemia as well as lesser response to treatment. Hence, a 
multi factorial logistic regression analysis was done to determine whether 
anemia was independently associated with response to treatment irrespective 
of age. It was observed that both age more than 60 years and presence of 
anemia were independently and significantly associated with a higher risk of 
not attaining complete response (9 fold and 17 fold higher risk respectively). 
Age > 60 years is included in the IPI score and is a well known prognostic 
factor. However, the association of anemia with response to treatment, 
irrespective of age, is an interesting finding in this study. Several studies have 
reported on the prognostic significance of anemia in NHL. Gallagher reported 
that anemic patients had a lower incidence of CR compared to non anemic 
patients with DLBCL treated with R-CHOP chemotherapy (59% vs. 81%). 
Anemic patients also had a higher mortality rate, (37% vs. 16%), shorter 
median PFS [18 (0.7-52+) vs. 30 (2-57+) mos.], and shorter median OS [17 
(0.8-59+) vs. 34 (5-60+) mos.]. In this study, 15 (56%) of the 27 anemic 
patients received erythropoietin stimulating agents (ESA).and they observed 
that, anemic patients  who responded to ESA treatment (4/15) had a higher 
rate of CR (3/4 vs. 4/11)
[71].
This is an interesting finding as erythropoietin can 
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then serve as an important treatment for patients with NHL having anemia. 
However, one should remember the negative impact of ESA on 
thromboembolic events and survival, especially when hemoglobin is raised 
above 12 g/dl in chemotherapy induced anemia. Randomized controlled trials 
are required to establish the role of ESA in such settings.   
Other  studies have  also reported that anemia before chemotherapy or 
radiotherapy can have a negative correlation with survival
[7,57,65,68,69,80]
 and 
also decreases response to therapy
[59,64,70]
. The impact of anemia on Follicular 
lymphoma is well known and is included in the FLIPI 
[11]
. Gallager and 
Romaguera have highlighted the prognostic significance of anemia in this 
subset of patients 
[57,79]
. There is limited data in the literature on the impact of 
pretreatment anemia on response to chemotherapy. Cowan et al analyzed the 
impact of anemia on the outcome of patients with high and intermediate grade 
NHL and found a negative correlation with survival 
[68].
      Bremnes reported 
decreased response to treatment in anemic patients in patients with high grade 
lymphoma in Norway 
[70] 
Stewart et al also found a negative correlation  of 
anemia with survival  in patients with low grade lymphoma treated with 
chemotherapy
.[80] 
Morel et al evaluated the factors that influence complete 
response in patients with NHL. He found that age >40 years, elevated LDH 
level, a low hemoglobin level (<10 g/dl), and presence of two or more extra 
nodal site involvement were associated with a poor response.  But complete 
remission was measured over a longer period after chemotherapy. More over, 
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these patients were treated with four different chemotherapy regimens 
[59].
This 
is similar to our study where patients received different chemotherapy 
regimens depending on the subtype of NHL. This was one of the limitations in 
the study. On the other hand, Morrow et al exclusively included patients with 
IGNHL treated with CHOP and uniformity in chemotherapy regimen was 
maintained. Response to chemotherapy was inversely associated with baseline 
hemoglobin. They concluded that baseline anemia in IGNHL should be 
identified and appropriately managed.  They analyzed the outcome of 546 
patients who were treated with CHOP chemotherapy from 1991 to 1999.  
Anemic patients (Hb <12 g/dl) had a higher percentage of no response 
/progression than patients without anemia. Anemia at baseline was diagnosed 
in 46.1% to 51.7% of patients in the no response/progression group, as 
compared with 35% baseline anemia overall 
[64]
 
 
Moullet et al studied 1077 patients with NHL and reported on the 
frequency and prognostic significance of anemia. They found that the overall 
survival (OS) and progression-free survival (PFS) were significantly shorter 
for patients who were anemic at diagnosis in an univariate analysis. Median 
survival was, respectively, 47 and 146 months for overall survival and 15 and 
64 months for progression-free survival depending on the presence and 
absence of anemia. .They also observed that anemia was significantly 
associated with a shorter overall survival in certain histological types of NHL 
such as Small Lymphocytic lymphoma and Lymphoplasmacytic lymphoma. 
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They also did  a multivariate analysis ,crossing anemia with significant 
variables for overall and progression-free survival ,and found that  anemia was 
an independent adverse prognostic factor for overall survival The inclusion  of  
hemoglobin value to the five variables of the International Prognostic Index 
was found to improve the predictive value of IPI for OS and PFS 
.[7]
 Dubravka 
et al have ,in fact , mentioned that anemia was not included as a part of the 
International Prognostic Index (IPI) because it was not tested when the index 
was developed
[63]
 
Studies Impact of anemia on response to treatment/ survival 
Moullet (7) Yes 
Morrow(64) Yes 
Gallagher(79) Yes 
Cowan(68) Yes 
Dixon(69) Yes 
Conlan(65) Yes 
Romaguera(57) Yes 
Stewart(80) Yes 
Dubravka(63) Yes 
Current study Yes 
 
Hence, we can summarize that various studies have shown a significant 
impact of anemia on response to treatment as well as on survival. However, 
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most of these studies were retrospective and the number of patients included 
was relatively small. Our study is a prospective study and the impact of 
anemia on response to treatment is significant and is independent of age. More 
such studies that include a larger number of patients and incorporate 
multivariate analyses to exclude confounding factors such as age and stage are 
needed to make definite conclusions about the impact of anemia on the 
prognosis of NHL.  
Our study did not find any significant association between anemia and 
chemotherapy related toxicity. More over, there was no significant worsening 
of anemia after chemotherapy. This is in concordance with the study on 
anemia in lymphoid malignancies by Dubravka et al ,who  concluded that 
chemotherapy  in the treatment of lympho-proliferative  disease does not 
worsen anemia, and anemia  is mostly a sign of the disease severity
.[63]
On the 
contrary, some studies have found age to be  a definite independent risk factor 
for neutropenia in patients older than 60 years with lymphoma in a number of 
prospective clinical trials of CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisone) or regimens with equivalent toxicity 
[81,82,83,84] 
.  
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Conclusion: 
 
Anemia is a common hematological abnormality in non-Hodgkin 
lymphoma. There are very few studies reporting on the frequency, distribution 
and prognostic impact of anemia on NHL. Our study was conducted with a 
view to throw some light on these aspects. The following conclusions may be 
drawn from this study: 
 The frequency of anemia may be higher in NHL patients in India 
compared to western countries as observed in our study.  
 Most common pattern of anemia was normocytic normochromic 
anemia. Median Hb was 10.4g/dl.  
 Anemia in NHL is multi factorial. The most common cause of anemia 
was anemia of chronic disease .This may be related to inflammation 
and cytokine release in the background of malignancy as reflected by 
the elevated CRP in these cases. 
 Median age of the study population was 59 years; Age > 60 years was 
significantly associated with anemia 
 There was no significant association of anemia with female sex  
 There was no significant association of anemia with specific subtype of 
NHL, B symptoms or elevated LDH 
 There was significant association of presence of anemia with bone 
marrow involvement. 
64 
  There was significant association of anemia with attainment of 
response to treatment both on univariate and multivariate analysis, 
independent of age. 
 There was no significant association of anemia with chemotherapy 
related toxicity and there was no significant worsening of anemia after 
treatment. 
Limitations: 
One major limitation of the study was the heterogeneity of the study 
population. Patients with different subtypes of NHL treated with different 
chemotherapy regimen were included and impact of anemia on the outcome of 
a particular subtype could not be assessed. Also, the toxicity profile of 
different chemotherapy regimens is likely to be different. Another limitation 
was the short period of study, as a result of which, the impact of anemia on 
disease free survival and overall survival was not analyzed. One of the other 
drawbacks is that age was the only factor included in the multivariate analysis 
to assess the association of anemia on CR. This is because, we found a 
significant association of age with CR as well as with anemia and it is a well 
known prognostic factor in NHL. However, other factors such as stage and sex 
are also important. More over, a larger number of patients is needed to draw 
more definite conclusions in this regard.         
Anemia may have an independent prognostic impact on the outcome of 
patients with NHL. This study highlights the need for further prospective 
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studies, including larger number of patients, to establish such association, if 
any. This study is relevant in the Indian context as the prevalence of anemia is 
much higher in India compared to western countries
[85].
 In our study, we found 
a high frequency of anemia even when a cut off level of 11g/dl was considered 
to define anemia prompting evaluation, as per the National Comprehensive 
Cancer Network (NCCN) guidelines
[86].
  
Anemia may also be correctable in most cases and the negative impact 
of anemia on response or survival may be overcome by timely intervention. 
Hence, it is extremely important to investigate the causes of anemia in any 
patient with malignancy It is equally essential to explore the possibility of 
anemia as an independent prognostic factor in NHL in future prospective 
studies. This can have a major impact on the overall management of patients 
with non-Hodgkin lymphoma. 
 
 a 
 Proforma 
Name:                                       age:                               sex: 
UHID number:                    Index number:          Date of presentation:    
Diagnosis:              
Subtype:      Stage:     IPI: 
Extranodal sites:  Y/N 
B symptoms: Y/N 
Bone marrow involved: Y/N 
COMPLETE HEMOGRAM 
Total WBC count :                         Hb:               Platelet Count:        DC: 
MCV :                      MCH:                           MCHC:    Hct:        
Reticulocyte count:                   reticulocyte index:>2.5/ <2.5 
 Peripheral smear: Normocytic/Microcytic/Macrocytic 
IRON INDICES: 
Serum iron:                 Serum ferritin:            TIBC:              %saturation: 
 
 b 
OTHER LAB INVESTIGATIONS 
Serum Vitamin B12:              Serum folic acid: Coombs test:+/- 
Serum LDH:              CRP:              stool occult blood/ stool 
RE:  
BONE MARROW STUDY 
Morphology Cellularity: 
Iron stain: 1+/2+/3+/4                                bone marrow biopsy: +/- 
Type of anemia: 
Chemotherapy regimen: 
Blood transfusion given before chemotherapy : Y/N 
Response after 4 cycles : CR/ PR/ Stable disease/ progression 
CR after 4 cycles: Y/ N 
Chemotherapy related toxicity : Y/ N 
Type of toxicity: 1.                       2.                              3. 
Grade of toxicity: 1/2/3/4                1/2/3/4                       1/2/3/4              
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